Ana S André, Joana N R Dias, Sandra Aguiar, Sara Nogueira, Pedro Bule, Joana Inês Carvalho, João P M António, Marco Cavaco, Vera Neves, Soraia Oliveira, Gonçalo Vicente, Belmira Carrapiço, Berta São Braz, Barbara Rütgen, Lurdes Gano, João D G Correia, Miguel Castanho, Joao Goncalves, Pedro M P Gois, Solange Gil, Luís Tavares, Frederico Aires-da-Silva
Antibody-drug conjugates (ADCs) are among the fastest-growing classes of therapeutics in oncology. Although ADCs are in the spotlight, they still present significant engineering challenges. Therefore, there is an urgent need to develop more stable and effective ADCs. Most rabbit light chains have an extra disulfide bridge, that links the variable and constant domains, between Cys80 and Cys171, which is not found in the human or mouse. Thus, to develop a new generation of ADCs, we explored the potential of rabbit-derived VL-single-domain antibody scaffolds (sdAbs) to selectively conjugate a payload to Cys80...
March 24, 2023: Scientific Reports